Close Menu

More articles about Molecular Diagnostics

The company plans to transition its DetermaIO test from research to clinical use and to launch a new research product for immunotherapy monitoring by the end of this year.

The firms plan to build a workflow for CTC isolation directly from a patient's bloodstream for single-cell downstream molecular analysis such as sequencing, genotyping, or digital PCR.

The deal covers SpeeDx's ResistancePlus and PlexPCR product lines, which include tests for sexually transmitted infections and antibiotic resistance.

The test returns results in less than 30 minutes and has shown 97 percent sensitivity and 96 percent specificity in both symptomatic and asymptomatic people.

XPhyto said it is in discussions with potential distribution and wholesale partners as well as potential licensees for the SARS-CoV-2 molecular test.

Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.

The company uses next-generation sequencing data to track the health of transplanted organs and stem cells over time.

For the three months ended Dec. 31, the Boulder, Colorado-based firm reported revenues of $27.0 million compared to $8.3 million in 2019.

Still early in its clinical testing operations, the company shrank its net loss to $6.3 million or $.09 per share during the quarter.

Roche Diagnostics CEO Thomas Schinecker said the infrastructure put in place due to the pandemic will allow for more diagnostic testing globally.

The startup will use the funds to support R&D and to launch its Qsant urine test to help determine if a patient's body is rejecting a kidney transplant.

The survey found analysis, interpretation, and reporting requirements can take more than six hours per test but that reimbursement for tests doesn't account for this work.

The competitive contracts support sequencing of random positive patient samples by the commercial diagnostic labs.

The winning teams used a variety of technologies for their tests, including rapid PCR, antigens, point-of-care LAMP, olfaction, and breathalyzers.

The deal to create a comprehensive genomic profiling test for Illumina's NextSeq 550Dx comes months after the instrument received regulatory approval in China.

NeoGenomics will use its gene fusion panels to identify patients with solid tumors and an NRG1 fusion who might qualify for Elevation's Phase II CRESTONE study. 

The lab will perform DNA and RNA sequencing as well as well as liquid biopsy analyses to advance precision oncology in New Jersey and the East Coast.

The firm said it will use the financing to develop and commercialize its immune response gene-expression diagnostic tests.

The company said clinical lab revenues rose 92 percent during the quarter, driven by significant volume and pricing growth due to an improved product mix.

Boston-based Variantyx will expand its whole-genome sequencing testing method to oncology from rare inherited and neurological disorders.


NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.